A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

NCT06507306 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult

Interventions

DRUG: KQB198
DRUG: Osimertinib
DRUG: Amivantamab

Sponsor

Kumquat Biosciences Inc.